Huaqun Chen

Prof. Huaqun Chen


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PWPei Wang
Pei Wang
WZWei Zhao
Wei Zhao
JSJie Sun
Jie Sun
TTTao Tao
Tao Tao
XCXin Chen
Xin Chen
MZMin-Sheng Zhu
Min-Sheng Zhu

27 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JLJianming Liu
Jianming Liu
ZHZhan-Peng Huang
Zhan-Peng Huang
MNMao Nie
Mao Nie
GWGang Wang
Gang Wang
WSWilliam J. Silva
William J. Silva
DWDa-Zhi Wang
Da-Zhi Wang
The appropriate arrangement of myonuclei within skeletal muscle myofibers is of critical importance for normal muscle function, and improper myonuclear localization has been linked to a variety of skeletal muscle diseases, such as centronuclear myopathy and muscular dystrophies. However, the molecules that govern myonuclear positioning remain elusive. Here, we report that skeletal muscle-specific CIP (sk-CIP) is a regulator of nuclear positioning. Genetic deletion of sk-CIP in mice results in misalignment of myonuclei along the myofibers and at specialized structures such as neuromuscular junctions (NMJs) and myotendinous junctions (MTJs) in vivo, impairing myonuclear positioning after muscle regeneration, leading to severe muscle dystrophy in mdx mice, a mouse model of Duchenne muscular dystrophy. sk-CIP is localized to the centrosome in myoblasts and relocates to the outer nuclear envelope in myotubes upon differentiation. Mechanistically, we found that sk-CIP interacts with the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex and the centriole Microtubule Organizing Center (MTOC) proteins to coordinately modulate myonuclear positioning and alignment. These findings indicate that sk-CIP may function as a muscle-specific anchoring protein to regulate nuclear position in multinucleated muscle cells. Significance The arrangement of nuclei in myofibers, which are multinucleated skeletal muscle cells, is essential for their proper function. Abnormal nuclear positioning in myofibers is a common feature of several skeletal muscle diseases, including centronuclear myopathy and muscular dystrophy. Here, we show an isoform of the CIP protein (sk-CIP) contributes to the regulation of the positioning of nuclei in myofibers by interacting with both the LINC complex (Linker of Nucleoskeleton and Cytoskeleton) and proteins in the microtubule-organizing center (MTOC). Through these interactions, sk-CIP appears to function as a skeletal muscle-specific anchoring protein that regulates nuclear positioning in myofibers. Further investigation and understanding of myofiber nuclear positioning may facilitate the development of novel therapies for some diseases of skeletal muscle.

23 June 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YZYu-Wei Zhou
Yu-Wei Zhou
JSJie Sun
Jie Sun
YWYe Wang
Ye Wang
CCCai-Ping Chen
Cai-Ping Chen
TTTao Tao
Tao Tao
MZMin-Sheng Zhu
Min-Sheng Zhu
Both chronic obstructive pulmonary disease (COPD) and asthma are severe respiratory diseases. Bitter receptor–mediated bronchodilation is a potential therapy for asthma, but the mechanism underlying the agonistic relaxation of airway smooth muscle (ASM) is not well defined. By exploring the ASM relaxation mechanism of bitter substances, we observed that pretreatment with the bitter substances nearly abolished the methacholine (MCh)-induced increase in the ASM cell (ASMC) calcium concentration, thereby suppressing the calcium-induced contraction release. The ASM relaxation was significantly inhibited by simultaneous deletion of three Gα t proteins, suggesting an interaction between Tas2R and AChR signaling cascades in the relaxation process. Biochemically, the Gα t released by Tas2R activation complexes with AChR and blocks the Gα q cycling of AChR signal transduction. More importantly, a bitter substance, kudinoside A, not only attenuates airway constriction but also significantly inhibits pulmonary inflammation and tissue remodeling in COPD rats, indicating its modulation of additional Gα q -associated pathological processes. Thus, our results suggest that Tas2R activation may be an ideal strategy for halting multiple pathological processes of COPD.

10 June 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YZYiteng Zhang
Yiteng Zhang
CZChenghai Zhang
Chenghai Zhang
HZHe Zhang
He Zhang
WZWeiwei Zeng
Weiwei Zeng
SLShuai Li
Shuai Li
HCHuaqun Chen
Huaqun Chen
The paracellular gap formed by endothelial cell (EC) contraction is fundamental for endothelium permeability, but the mechanism underlying EC contraction has yet to be determined. Here, we identified the zipper‐interacting protein kinase (ZIPK) as the kinase for EC contraction and myosin light chain (MLC) phosphorylation. Inhibition of ZIPK activity by pharmacological inhibitors and small interfering RNAs led to a significant decrease in the mono‐ and diphosphorylation of MLCs along with a contractile response to thrombin, suggesting an essential role of ZIPK in EC paracellular permeability. To assess the role of ZIPK in vivo , we established mouse lines with conditional deletion of Zipk gene. The endothelium‐specific deletion of Zipk led to embryonic lethality, whereas the UBC‐Cre ERT2 –mediated deletion of Zipk by tamoxifen induction at adulthood caused no apparent phenotype. The induced deletion of Zipk significantly inhibited ischemia‐reperfusion‐induced blood‐brain barrier dysfunction and neuronal injuries from middle cerebral artery occlusion and reperfusion, as evidenced by reduced infarct and edema volume, attenuated Evans blue dye leakage, and improved neuronal behavior. We thus concluded that ZIPK and its phosphorylation of MLC were required for EC contraction and ischemic neuronal injuries. ZIPK may be a prospective therapeutic target for stroke.—Zhang, Y., Zhang, C., Zhang, H., Zeng, W., Li, S., Chen, C., Song, X., Sun, J., Sun, Z., Cui, C., Cao, X., Zheng, L., Wang, P., Zhao, W., Zhang, Z., Xu, Y., Zhu, M., Chen, H. ZIPK mediates endothelial cell contraction through myosin light chain phosphorylation and is required for ischemic‐reperfusion injury. FASEB J. 33, 9062–9074 (2019). www.fasebj.org

20 November 2025 in Science
Verified
Journal Article
Closed access
ZJZhihui Jiang
Zhihui Jiang
YWYe Wang
Ye Wang
JGJianfeng Gong
Jianfeng Gong
XCXin Chen
Xin Chen
DHDong Hang
Dong Hang
MZMin-Sheng Zhu
Min-Sheng Zhu
Ulcerative colitis (UC) is a severe inflammatory bowel disease affecting millions of people worldwide, but the factors driving the condition are poorly understood. In tissue samples from individuals with UC, we found that macrophages were depleted from areas of the colon that did not yet exhibit overt epithelial inflammation. We hypothesized that toxins produced by bacteria could impair macrophages and that this could promote wider inflammation. We isolated a variant of Aeromonas genus from stool samples from UC patients, which we termed macrophage-toxic bacteria (MTB), because aerolysin secreted by MTB caused macrophage death. MTB colonized mice under pathogenic conditions and triggered colitis. Antibodies against aerolysin alleviated colitis induced by Aeromonas in mice. In a cohort, UC patients more frequently tested positive for Aeromonas than healthy controls did.

24 September 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GZGuang-Jie Zhu
Guang-Jie Zhu
SGSihao Gong
Sihao Gong
DMDeng-Bin Ma
Deng-Bin Ma
TTTao Tao
Tao Tao
WHWeiqi He
Weiqi He
GWGuoqiang Wan
Guoqiang Wan
Genetic hearing loss is a common health problem with no effective therapy currently available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common forms of autosomal dominant non-syndromic deafness. In this study, we established a novel mouse model of the human DFNA15 deafness, with a Pou4f3 gene mutation (Pou4f3Δ) identical to that found in a familial case of DFNA15. The Pou4f3(Δ/+) mice suffered progressive deafness in a similar manner to the DFNA15 patients. Hair cells in the Pou4f3(Δ/+) cochlea displayed significant stereociliary and mitochondrial pathologies, with apparent loss of outer hair cells. Progression of hearing and outer hair cell loss of the Pou4f3(Δ/+) mice was significantly modified by other genetic and environmental factors. Using Pou4f3(-/+) heterozygous knockout mice, we also showed that DFNA15 is likely caused by haploinsufficiency of the Pou4f3 gene. Importantly, inhibition of retinoic acid signaling by the aldehyde dehydrogenase (Aldh) and retinoic acid receptor inhibitors promoted Pou4f3 expression in the cochlear tissue and suppressed the progression of hearing loss in the mutant mice. These data demonstrate Pou4f3 haploinsufficiency as the main underlying cause of human DFNA15 deafness and highlight the therapeutic potential of Aldh inhibitors for treatment of progressive hearing loss. More than 50% of deafness cases are due to genetic defects with no treatment available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common types of autosomal dominant non-syndromic deafness. Here, we established a novel mouse model with the exact Pou4f3 mutation identified in human patients. The mutant mouse display similar auditory pathophysiology as human patients and exhibit multiple hair cell abnormalities. The onset and severity of hearing loss in the mouse model is highly modifiable to environmental factors, such as aging, noise exposure or genetic backgrounds. Using a new knockout mouse model, we found Pou4f3 haploinsufficiency as the underlying mechanism of human DFNA15. Importantly, we identified Aldh inhibitor as a potent small molecule for upregulation of Pou4f3 and treatment of hearing loss in the mutant mouse. The identification of Aldh inhibitor for treatment of DFNA15 deafness represents a major advance in the unmet medical need for this common form of progressive hearing loss.